Sign in or Register   Sign in or Register
  |  

Mouse Anti-ANGPTL4 Recombinant Antibody (Kairos4-153AD) (CBMAB-A2727-YC)

Provided herein is a Mouse monoclonal antibody against Human Angiopoietin Like 4. The antibody can be used for immunoassay techniques, such as ELISA, WB.
See all ANGPTL4 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
Kairos4-153AD
Antibody Isotype
IgG1, κ
Application
ELISA, WB

Basic Information

Immunogen
Recombinant human coiled-coil domain of ANGPTL4
Host Species
Mouse
Specificity
Human
Antibody Isotype
IgG1, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
WB1:500-1:5,000
ELISA1:500-1:5,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, pH 7.4
Preservative
None
Concentration
0.5 mg/ml
Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
angiopoietin-like 4
Introduction
ANGPTL4 is a glycosylated, secreted protein containing a C-terminal fibrinogen domain. The encoded protein is induced by peroxisome proliferation activators and functions as a serum hormone that regulates glucose homeostasis, lipid metabolism, and insulin
Entrez Gene ID
51129
UniProt ID
Q9BY76
Alternative Names
Angiopoietin Like 4; Hepatic Fibrinogen/Angiopoietin-Related Protein; Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Induced Angiopoietin-Related Protein; Hepatic Angiopoietin-Related Protein; PPARG Angiopoietin Related Protein; Fasting-Induced A
Function
Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism (PubMed:19270337, PubMed:21398697, PubMed:27929370, PubMed:29899144). May also play a role in regulating glucose homeostasis and insulin sensitivity (Probable). Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage (PubMed:14583458, PubMed:17068295). Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro) (PubMed:17068295). Depending on context, may modulate tumor-related angiogenesis (By similarity).
ANGPTL4 N-terminal chain: Mediates inactivation of the lipoprotein lipase LPL, and thereby plays an important role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism (PubMed:19270337, PubMed:21398697, PubMed:27929370, PubMed:29899144). Has higher activity in LPL inactivation than the uncleaved protein (PubMed:19270337, PubMed:21398697).
Biological Process
Angiogenesis Source: UniProtKB-KW
Lipid metabolic process Source: UniProtKB-KW
Negative regulation of apoptotic process Source: UniProtKB
Negative regulation of endothelial cell apoptotic process Source: Ensembl
Negative regulation of lipoprotein lipase activity Source: BHF-UCL
Positive regulation of angiogenesis Source: UniProtKB
Protein unfolding Source: ARUK-UCL
Regulation of metabolic process Source: Reactome
Response to hypoxia Source: UniProtKB
Triglyceride homeostasis Source: BHF-UCL
Cellular Location
Secreted; Extracellular matrix. The unprocessed form interacts with the extracellular matrix (PubMed:17068295, PubMed:21398697). This may constitute a dynamic reservoir, a regulatory mechanism of the bioavailability of ANGPTL4 (Probable).
PTM
N-glycosylated.
ANGPTL4 N-terminal chain: Forms disulfide-linked dimers and tetramers.
Cleaved into a smaller N-terminal chain and a larger chain that contains the fibrinogen C-terminal domain; both cleaved and uncleaved forms are detected in the extracellular space. The cleaved form is not present within the cell.

Sodhi, A., Ma, T., Menon, D., Deshpande, M., Jee, K., Dinabandhu, A., ... & Montaner, S. (2019). Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema. The Journal of clinical investigation, 129(11), 4593-4608.

Theofilatos, D., Fotakis, P., Valanti, E., Sanoudou, D., Zannis, V., & Kardassis, D. (2018). HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway. Metabolism, 87, 36-47.

Dijk, W., Ruppert, P. M., Oost, L. J., & Kersten, S. (2018). Angiopoietin-like 4 promotes the intracellular cleavage of lipoprotein lipase by PCSK3/furin in adipocytes. Journal of Biological Chemistry, 293(36), 14134-14145.

Zhang, T., Kastrenopoulou, A., Larrouture, Q., Athanasou, N. A., & Knowles, H. J. (2018). Angiopoietin-like 4 promotes osteosarcoma cell proliferation and migration and stimulates osteoclastogenesis. BMC cancer, 18(1), 1-10.

Dijk, W., Schutte, S., Aarts, E. O., Janssen, I. M., Afman, L., & Kersten, S. (2018). Regulation of angiopoietin-like 4 and lipoprotein lipase in human adipose tissue. Journal of clinical lipidology, 12(3), 773-783.

Janssen, A. W., Katiraei, S., Bartosinska, B., Eberhard, D., van Dijk, K. W., & Kersten, S. (2018). Loss of angiopoietin-like 4 (ANGPTL4) in mice with diet-induced obesity uncouples visceral obesity from glucose intolerance partly via the gut microbiota. Diabetologia, 61(6), 1447-1458.

Yang, X., Cheng, Y., & Su, G. (2018). A review of the multifunctionality of angiopoietin-like 4 in eye disease. Bioscience reports, 38(5).

Cushing, E. M., Chi, X., Sylvers, K. L., Shetty, S. K., Potthoff, M. J., & Davies, B. S. (2017). Angiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting. Molecular metabolism, 6(8), 809-818.

McQueen, A. E., Kanamaluru, D., Yan, K., Gray, N. E., Wu, L., Li, M. L., ... & Wang, J. C. (2017). The C-terminal fibrinogen-like domain of angiopoietin-like 4 stimulates adipose tissue lipolysis and promotes energy expenditure. Journal of Biological Chemistry, 292(39), 16122-16134.

Cara-Fuentes, G., Segarra, A., Silva-Sanchez, C., Wang, H., Lanaspa, M. A., Johnson, R. J., & Garin, E. H. (2017). Angiopoietin-like-4 and minimal change disease. PloS one, 12(4), e0176198.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-ANGPTL4 Recombinant Antibody (Kairos4-153AD)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare